Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Nov;18(11):e015546.
doi: 10.1161/CIRCINTERVENTIONS.125.015546. Epub 2025 Sep 17.

Patterns of Restenosis After Left Main Bifurcation Single- or Dual-Stenting: An EBC MAIN Trial Subanalysis

Affiliations
Randomized Controlled Trial

Patterns of Restenosis After Left Main Bifurcation Single- or Dual-Stenting: An EBC MAIN Trial Subanalysis

Annette Maznyczka et al. Circ Cardiovasc Interv. 2025 Nov.

Abstract

Background: In the randomized EBC MAIN trial (European Bifurcation Club Left Main Coronary Stent), target lesion revascularization at 3 years poststenting of left main (LM) bifurcations was more frequent with upfront dual-stenting compared with the stepwise provisional approach. Restenosis location and its relation to stent technique are poorly characterized. The aim of this study was to investigate restenosis location after LM bifurcation stenting, and the impact of stent implantation technique.

Methods: Patients from the EBC MAIN trial who underwent target lesion revascularization during the 3-year follow-up had restenosis location assessed by the core laboratory. Restenosis was defined as ≥50% lesion diameter stenosis.

Results: Among 48 patients with target lesion revascularization (mean age 70.3±10.6 years, 72.9% men), 31 were randomized to and treated with upfront dual-stenting, while 17 were randomized to the stepwise provisional technique, of whom 4 had dual-stent implantation. The treatment groups therefore comprised 35 dual-stented and 13 single-stented patients. The commonest pattern of subsequent restenosis was isolated ostial circumflex restenosis (58% of patients), regardless of dual- or single-stent implantation. The ostial circumflex was the culprit lesion for target lesion revascularization in 34 (71%) patients overall (dual- versus single-stented patients: 77% versus 54%; P=0.115). During the 3-year follow-up, the mean % diameter stenosis at the circumflex ostium was similar after dual- versus single-stent implantation (64.6% versus 60.5%, coefficient, -0.12 [95% CI, -0.46 to 0.22]; P=0.473). Single stenting from LM to the circumflex artery was associated with worse subsequent mean % diameter stenosis in the ostium of the left anterior descending artery versus single stenting from LM- left anterior descending (49.8% versus 19.8%, coefficient, 0.57 [95% CI, 0.003-1.13]; P=0.049).

Conclusions: The circumflex ostium is the commonest site requiring revascularization after LM bifurcation stenting, irrespective of whether 1 or 2 stents were deployed. Strategies are needed to improve the long-term success of percutaneous coronary intervention to the circumflex artery ostium.

Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02497014.

Keywords: coronary vessels; follow-up studies; humans; percutaneous coronary intervention; stents.

PubMed Disclaimer

Conflict of interest statement

Dr Maznyczka: travel grants Edwards Lifesciences, Abbott, Boston Scientific, and Medtronic. Dr Hildick-Smith: Proctor/Advisory Boston, Abbott, Medtronic, Terumo, Edwards, Occlutech, and Gore; CERC. Dr Morice: CERC CEO. Dr Banning: Lecture fees Boston. Dr Lassen: Medtronic speaker fees, CERC. Dr Lefevre: Proctoring Abbott, Edwards Terumo, Lectures, Boston Scientific, and Medtronic speaker fees. Dr Egred: Honorarium, proctorship and speaker fees Abbott, Boston Scientific, Terumo, Phillips, Vascular Perspectives, Teleflex, and Miracor. Dr Erglis: Grant support Abbott and Boston Scientific. Dr Pan: Lecture fees Abbott, Boston, Philips, and Asahi. Dr Chieffo: Consultant Abiomed, Biosensor, Magenta; Speakers fees Abbott vascular, Abiomed, Boston Scientific, and Cardinal Health. Dr Stankovic: Speaker fees Abbott, Terumo, Boston Scientific, and Medtronic. The other authors report no conflicts.

Comment in

Publication types

MeSH terms

Associated data